Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Dec 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-12-22

Reporting Person: Eisele Jeffrey (Exec VP, Program Team Lead)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-22	Common Stock	F	89	$47.82	Disposed	7372	Direct

Footnotes

F1: This represents shares used to cover tax withholding on a Restricted Stock Unit release.